It's a big win for Eli Lilly in multibillion-dollar Alimta patent fight

Save

Eli Lilly just scored billions in additional sales. A federal judge decreed that an unusual patent on Lilly's cancer drug Alimta is valid. And that means the company keeps its Alimta exclusivity till 2022.